Upregulated Neuro-oncological Ventral Antigen 1 (NOVA1) Expression Is Specific to Mature and Immature T- and NK-Cell Lymphomas
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Recent studies have revealed that the splicing factor neuro-oncological ventral antigen 1 (NOVA1) is enriched in fibroblasts and accumulated T cells of tertiary lymphoid structures. In the present study, we investigated NOVA1 expression in various subtypes of mature and immature T- and natural killer (NK)-cell lymphomas as well as in various B-cell lymphoma subtypes. Methods: NOVA1 immunoexpression was evaluated in hyperplastic palatine tonsils (n = 20), Tand NK-cell lymphomas (n = 177), diffuse large B-cell lymphomas (n = 151), and other types of B cell lymphomas (n = 31). Nuclear staining intensity and percentage of positive tumor cells were graded. NOVA1 mRNA expression was analyzed in various lymphoma cell lines. Results: Tumor cells of T- and NK-cell lymphomas showed higher expression levels of NOVA1 than did normal paracortical T cells, and 56.5% of T- and NK-cell lymphoma cases showed diffuse and strong expression. The NOVA1 expression level varied according to the subtype; it was higher in angioimmunoblastic T-cell lymphoma, anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL), and T lymphoblastic leukemia/lymphoma (T-LBL), but it was lower in ALKpositive ALCL. In almost all B-cell lymphomas, NOVA1 expression was very low or negative. NOVA1 mRNA was also expressed in Jurkat, a T-LBL cell line. Conclusions: The present findings suggest that NOVA1 upregulation may be involved in certain subtypes of T- and NK-cell lymphomas, but not in B-cell lymphomas. Upregulated NOVA1 expression seems to be a specific biological feature of activated T cells such as T- and NK-cell lymphomas.
Abstract
Background: Recent studies have revealed that the splicing factor neuro-oncological ventral antigen 1 (NOVA1) is enriched in fibroblasts and accumulated T cells of tertiary lymphoid structures. In the present study, we investigated NOVA1 expression in various subtypes of mature and immature T- and natural killer (NK)-cell lymphomas as well as in various B-cell lymphoma subtypes. Methods: NOVA1 immunoexpression was evaluated in hyperplastic palatine tonsils (n = 20), Tand NK-cell lymphomas (n = 177), diffuse large B-cell lymphomas (n = 151), and other types of B cell lymphomas (n = 31). Nuclear staining intensity and percentage of positive tumor cells were graded. NOVA1 mRNA expression was analyzed in various lymphoma cell lines. Results: Tumor cells of T- and NK-cell lymphomas showed higher expression levels of NOVA1 than did normal paracortical T cells, and 56.5% of T- and NK-cell lymphoma cases showed diffuse and strong expression. The NOVA1 expression level varied according to the subtype; it was higher in angioimmunoblastic T-cell lymphoma, anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL), and T lymphoblastic leukemia/lymphoma (T-LBL), but it was lower in ALKpositive ALCL. In almost all B-cell lymphomas, NOVA1 expression was very low or negative. NOVA1 mRNA was also expressed in Jurkat, a T-LBL cell line. Conclusions: The present findings suggest that NOVA1 upregulation may be involved in certain subtypes of T- and NK-cell lymphomas, but not in B-cell lymphomas. Upregulated NOVA1 expression seems to be a specific biological feature of activated T cells such as T- and NK-cell lymphomas.
참고문헌 (17)
- Barash Y, "Deciphering the splicing code", Nature, 465, pp.53~59 (2010)
- de la Grange P, "Splicing factor and exon profiling across human tissues", Nucleic Acids Res, 38, pp.2825~2838 (2010)
- Merkin J, "Evolutionary dynamics of gene and isoform regulation in mammalian tissues", Science, 338, pp.1593~1599 (2012)
- Kalsotra A, "Functional consequences of developmentally regulated alternative splicing", Nat Rev Genet, 12, pp.715~729 (2011)
- Mallinjoud P, "Endothelial, epithelial, and fibroblast cells exhibit specific splicing programs independently of their tissue of origin", Genome Res, 24, pp.511~521 (2014)
- Yoon SO, "NOVA1 inhibition by miR-146b-5p in the remnant tissue microenvironment defines occult residual disease after gastric cancer removal", Oncotarget, 7, pp.2475~2495 (2016)
- Drayton DL, "Lymphoid organ development: from ontogeny to neogenesis", Nat Immunol, 7, pp.344~353 (2006)
- Ruddle NH, "Secondary lymphoid organs: responding to genetic and environmental cues in ontogeny and the immune response", J Immunol, 183, pp.2205~2212 (2009)
- Buckley CD, "Stromal cells in chronic inflammation and tertiary lymphoid organ formation", Annu Rev Immunol, 33, pp.715~745 (2015)
- Kalluri R, "Fibroblasts in cancer", Nat Rev Cancer, 6, pp.392~401 (2006)
- Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues" (2008), IARC Press
- 박은향, "Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma", Journal of Pathology and Translational Medicine, 49(5), pp.382~388 (2015), 대한병리학회[DOI]
- Falini B, "Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias", Haematologica, 92, pp.519~532 (2007)
- Kelemen O, "Function of alternative splicing", Gene, 514, pp.1~30 (2013)
- Oberdoerffer S, "Regulation of CD45 alternative splicing by heterogeneous ribonucleoprotein, hnRNPLL", Science, 321, pp.686~691 (2008)
- O’Rourke JP, "Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities", Mol Cell Biol, 28, pp.2091~2101 (2008)
- Henry C, "Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance", Blood, 115, pp.2420~2429 (2010)